The U.S. Federal Circuit has denied Teva's request for an en banc rehearing in a patent dispute concerning the Orange Book, a database that lists patents for approved drugs. This decision follows a series of recent rulings that emphasize caution in patent listings. Additionally, the Federal Circuit ruled that the U.S. International Trade Commission (ITC) incorrectly limited the definition of qualifying domestic industry activities. The court's decision allows for broader interpretations of domestic expenses related to sales and marketing, which could enable companies to pursue patent cases more effectively. This ruling also revived a lawsuit from Lashify, a company specializing in eyelash applicators, which had faced challenges under the ITC's previous interpretations.